RWS Gives Early Indication of Pandemic’s Impact on Translation Industry
The world’s most valuable listed language service provider RWS posts small decline in revenues in H1 FY 2020 and updates investors on impact of coronavirus pandemic.
*New* Slator Pro Guide: Scaling an LSP Key Account — Growing Small Clients into Key Accounts
RWS Life Sciences
RWS Delivers Another Strong Year as Strategic Bets Pay Off
Revenues, profits, and share price all rise strongly in 2019 as RWS’ strategic bets on Moravia, the United States, and premium verticals pay off. Revenues up 16% to USD 469m.
Slator 2019 Life Sciences Translation Report
Slator’s 2019 report on the clinical life sciences translation industry, analysis of the competitive landscape and actionable insights from major buyers of pharmaceutical translation.
RWS Simplifies Operating Structure as Cost Control and Moravia Boost Profits
RWS half-year results boosted by Moravia unit and strong IP business. Margins widen on simplification of operating structure, tight cost control.
Language Industry Hires at RWS, memoQ, Today Translations, and Teknotrans
RWS Life Sciences welcomes a new Vice President for Global and Quality Process while memoQ Translation Technologies appoints a new Inbound Marketing Manager. Today Translations and Teknotrans hire senior executives.
RWS Expands Global Offering with RWS Life Sciences
The acquisition of LUZ, Inc. and Corporate Translations, Inc. strengthens RWS’ market leadership and continued growth of life science language services.
Your information will not be shared with third parties. No Spam.